Scinai Immunotherapeutics Ltd.
corporate_fare Company Profile
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a publicly traded company in the Life Sciences sector. Wiseek monitors SCNI SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Shareholders Approve Massive Increase in Authorized Shares, Enabling Future Capital Raises
- Scinai Reports Q1 Results, Completes Strategic CDMO Acquisition with $6.2M Bargain Gain
- Scinai Reports Q1 Net Income of $3.6M from Non-Cash Gain; Operating Loss Widens to $2.5M Amid Cash Crunch
- Scinai Immunotherapeutics Registers Resale of 16.3 Million ADSs, Creating Massive Dilution Overhang
- Scinai Immunotherapeutics seeks massive share authorization increase and executive pay hikes amid delisting threat
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for SCNI, detected from its recent SEC filings · based on capital-structure filings through 2026-05-19.
Resale Registration Finalized · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SCNI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.